Evidence map›Paper›PMID 39966463›Full record

ArticleScientific reports2025

A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study.

Shi-Wei Hu, Xiu-di Yang, Di-Jiong Wu, Yi Wang, Xiao-Qiong Zhu, Wei-Ying Feng, Hong-Lan Qian, Ying Lu, Li-Li Chen, Li-Hong Cao and 26 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Shi-Wei Hu *Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiu-di Yang *Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Di-Jiong Wu *Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yi Wang *Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Xiao-Qiong ZhuDepartment of Hematology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
Wei-Ying FengDepartment of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Hong-Lan QianDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ying LuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Li-Li ChenDepartment of Hematology, The First People's Hospital of Taizhou, Taizhou, Zhejiang, China.
Li-Hong CaoDepartment of Hematology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China.
Jing LeDepartment of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.
Li ZhangDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Yan-Ping ShaoDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Li-Rong LiuDepartment of Hematology, The Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Guo-Yan TianDepartment of Hematology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
Hui ZhouDepartment of Hematology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
Yu ChenDepartment of Hematology, College of Medicine, Lishui Hospital, Zhejiang University, Lishui, Zhejiang, China.
Xiu-Feng YinDepartment of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiao-Ning FengDepartment of Hematology, Lishui People's Hospital, Lishui, Zhejiang, China.
Li HuangDepartment of Hematology, The Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, Zhejiang, China.
Kai-Feng ZhangDepartment of Hematology, Xinchang County People's Hospital, Xinchang, Zhejiang, China.
Yong-Ming XiaDepartment of Hematology, The Affliated Yangming Hospital of Ningbo University Yuyao People's Hospital of Zhejiang Province, Yuyao, Zhejiang, China.
Lin-Juan XuDepartment of Hematology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Hui-Qi ZhangDepartment of Hematology, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Gang ZhangDepartment of Hematology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Yong-Qing JiaDepartment of Hematology, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.
Xiu-Jie ZhouDepartment of Hematology, Haining People's Hospital, Haining, Zhejiang, China.
Gong-Qiang WuDepartment of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Jin-Ming TuDepartment of Hematology, The People's Hospital of Longyou City, Longyou, Zhejiang, China.
Feng ZhuDepartment of Hematology, Zhoushan Hospital, Zhejiang University School of Medicine, Zhoushan, Zhejiang, China.
Yue-Feng ZhangDepartment of Hematology, First People's Hospital of Linping District, Hangzhou, Zhejiang, China.
Guo-Li YaoDepartment of Hematology, First People's Hospital of Linping District, Hangzhou, Zhejiang, China.
Jing-Jing ZhuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Hong-Yan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. jiej0503@zju.edu.cn.
Jian HuangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. househuang@zju.edu.cn.

Funding

Key R&D Program of Zhejiang No. 2022C03137Zhejiang Medical Association Clinical Medical Research Special Fund Project No. 2022ZYC-D09
6 · The paper itself

Abstract

The T315I mutation poses a significant threat to patients with chronic phase chronic myeloid leukemia (CP-CML). This study aimed to establish a nomogram to predict the risk of T315I mutation in CP-CML patients. The training cohort included 1,466 patients from 24 hematology centers, and the validation cohort included 820 patients from an additional 20 centers. Peripheral blood blast (PBB), additional chromosomal abnormality (ACA), dasatinib use, non-EMR at 3 months, and BCR::ABL

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myeloid, Chronic-PhaseMutationNomogramsAdolescentAdultAgedDisease-Free SurvivalFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisRetrospective StudiesROC CurveFusion Proteins, bcr-ablChronic myeloid leukemiaPrediction nomogramT315I mutation

Identifiers

PMID39966463
PMCPMC11836442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.